Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Gilead Sciences

If You Have Chronic Hepatitis B, a New FDA Approval Means You Should Ask About This Dangerous Co-Infection

A new FDA approval for Hepatitis Delta treatment means chronic hepatitis B patients should now ask about HDV testing. Here's why testing matters more than ever and who should ask.

The FDA Approves the First-Ever Hepatitis Delta Treatment: Here's Why Hepatitis B Patients Should Get Tested

The FDA Approves the First-Ever Hepatitis Delta Treatment: Here's Why Hepatitis B Patients Should Get Tested

FDA approved bulevirtide May 22, 2026 — the first-ever Hepatitis Delta treatment. About 80,000 Americans have HDV. Here's who should ask for testing and what the approval means.

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Hepatitis Delta Is the Deadliest Form of Viral Hepatitis — and the U.S. Just Got Its First Treatment for It

FDA granted accelerated approval to Hepcludex (bulevirtide) for Hepatitis Delta on May 22, 2026 — the first-ever U.S. treatment for HDV. What patients need to know.

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event. Okazaki said 2024 w

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel

Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline

Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development. Speaking at the Bank of America Healthca

inkl

Read news from The Economist, FT, and more,
with one subscription

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Though Gilead Sciences has underperformed relative to the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Why this Gilead Sciences exec says managing energy, not time, drives performance

Why this Gilead Sciences exec says managing energy, not time, drives performance

At Gilead Sciences, its chief commercial officer says managing energy matters more than managing time.

2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch

2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch

By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights.

3 Top-Rated Stocks to Buy to Hedge Against Stagflation as Middle East Conflict Drags On

3 Top-Rated Stocks to Buy to Hedge Against Stagflation as Middle East Conflict Drags On

Amid widespread uncertainties, these three names can shield your portfolio.

A long-acting HIV drug arrives in Zimbabwe for some at highest risk

A long-acting HIV drug arrives in Zimbabwe for some at highest risk

Zimbabwe is one of the world's first countries to roll out lenacapavir, a long-acting HIV prevention drug that is administered only twice a year

The Independent UK

Stock Index Futures Muted With U.S. Retail Sales Data in Focus

Stock Index Futures Muted With U.S. Retail Sales Data in Focus

March S&P 500 E-Mini futures (ESH26) are up +0.03%, and March Nasdaq 100 E-Mini futures (NQH26) are up +0.04% this morning, taking a breather after a recent rally as investors await a slew of U.S. economic data, with particular attention on the retail sales report, remarks from Federal Reserve officials,…

This Overlooked Biotech Giant Could Surprise Investors This Quarter

This Overlooked Biotech Giant Could Surprise Investors This Quarter

Investors may be underestimating the long-term potential of Gilead’s evolving portfolio.

Get all your
news in one place.

100's of premium titles.
One news app.

Gilead Sciences Earnings Preview: What to Expect

Gilead Sciences is expected to release its fiscal fourth-quarter earnings soon, and analysts project a decline in EPS.

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

The Independent UK

World is so close to ending Aids pandemic but must keep funding ‘miracle’ drugs, UN chief warns

IN FOCUS: Cutting-edge prevention drugs – hailed as being able to reduce new infections to zero – could see the end of the Aids pandemic, as long as funding continues amid massive cuts, UNAIDS chief tells chief international correspondent Bel Trew

The Independent UK

Eswatini is the first African country to get twice-yearly HIV prevention shot

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global health officials call a game-changer

Get all your
news in one place.

100's of premium titles.
One news app.

3 Cash-Rich Stocks With High Growth Potential Right Now

Discover three high free cash flow yield stocks—Salesforce, Applied Materials, and Gilead Sciences—offering stability and long-term growth potential

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.

Is Wall Street Bullish or Bearish on Gilead Sciences Stock?

Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.

The Independent UK

South Africa's health minister hails new HIV prevention jab but warns of limited supply

South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool against the disease

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences, Inc. (NASDAQ:GILD) as his final trade.

Gilead Reaches Settlement To Block Biktarvy Generics Until 2036

Gilead Sciences, Inc. (NASDAQ:GILD) on Monday entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration to market generic versions of Biktarvy.

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

1 2 3 4 5

People

208,015 stories

Sir Keir Starmer

Winnie Byanyima

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Corporate Earnings

Places

408,020 stories

146,610 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play